Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

calcium acetate

×

Overview

What is Phoslyra?

PHOSLYRA acts as a phosphate binder.  Its chemical name is calcium acetate.  Its molecular formula is C H CaO , and its molecular weight is 158.17.  Its structural formula is:

PHOSLYRA for oral administration is provided as pale to light greenish-yellow clear liquid.  Each 5 mL of PHOSLYRA contains 667 mg calcium acetate, USP equal to 169 mg (8.45 mEq) calcium.  PHOSLYRA also contains the following inactive ingredients:  maltitol NF, glycerin USP, Magnasweet 110, propylene glycol USP, povidone K25 USP, sucralose NF, methylparaben NF, artificial black cherry flavor, menthol flavor, purified water USP.



What does Phoslyra look like?



What are the available doses of Phoslyra?

Oral Solution:  667 mg calcium acetate per 5 mL.

What should I talk to my health care provider before I take Phoslyra?

How should I use Phoslyra?

PHOSLYRA is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).

Management of elevated serum phosphorus levels usually includes all of the following:  reduction in dietary intake of phosphate, removal of phosphate by dialysis, and inhibition of intestinal phosphate absorption with phosphate binders.

The recommended initial dose of PHOSLYRA for the adult dialysis patient is 10 mL with each meal.  Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop.  Titrate the dose every 2 to 3 weeks until an acceptable serum phosphorus level is reached.  Most patients require 15-20 mL with each meal.


What interacts with Phoslyra?

Sorry No Records found


What are the warnings of Phoslyra?

Sorry No Records found


What are the precautions of Phoslyra?

Sorry No Records found


What are the side effects of Phoslyra?

Sorry No records found


What should I look out for while using Phoslyra?

Patients with hypercalcemia.


What might happen if I take too much Phoslyra?

Administration of PHOSLYRA in excess of the appropriate daily dosage may result in hypercalcemia .


How should I store and handle Phoslyra?

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light. PHOSLYRA for oral administration is a clear solution containing 667 mg calcium acetate per 5 mL.  PHOSLYRA is supplied in amber-colored, multiple-dose bottles, packaged with a marked dosing cup in the following size:473 mL (16 fl. oz) bottle............................................................................. (NDC 49230-643-31)PHOSLYRA for oral administration is a clear solution containing 667 mg calcium acetate per 5 mL.  PHOSLYRA is supplied in amber-colored, multiple-dose bottles, packaged with a marked dosing cup in the following size:473 mL (16 fl. oz) bottle............................................................................. (NDC 49230-643-31)


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium-phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentrations.

Non-Clinical Toxicology
Patients with hypercalcemia.

Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (PHOSLYRA).  Avoid the concurrent use of calcium supplements, including calcium-based nonprescription antacids, with PHOSLYRA.

An overdose of PHOSLYRA may lead to progressive hypercalcemia, which may require emergency measures.  Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly.  Should hypercalcemia develop, reduce the PHOSLYRA dosage or discontinue the treatment, depending on the severity of hypercalcemia.

More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma.  Severe hypercalcemia can be treated by acute hemodialysis and discontinuing PHOSLYRA therapy.

Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting.  Mild hypercalcemia is usually controlled by reducing the PHOSLYRA dose or temporarily discontinuing therapy.  Decreasing or discontinuing Vitamin D therapy is recommended as well.

Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification.  Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft-tissue calcification.  The long-term effect of PHOSLYRA on the progression of vascular or soft-tissue calcification has not been determined.

Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of a solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.

Maintain the serum calcium-phosphorus (Ca × P) product below 55 mg /dL .

No clinical trials have been performed with PHOSLYRA in the intended population.  Because the dose and active ingredients of PHOSLYRA are equivalent to that of the calcium acetate gelcaps or tablets, the scope of the adverse reactions is anticipated to be similar.

Hypercalcemia is discussed elsewhere .

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).